

Contents

Problems and Prospects of Discovering New Drugs from Higher Plants by Pharmacological Screening N.R. FARNSWORTH and A.S. BINGEL	1
A. Introduction	1
B. Value of Drugs Obtained from Higher Plants	1
I. Commercial Value of Plant-Derived Drugs	1
II. Role of Plant-Derived Drugs as Therapeutic Agents	3
III. Uses Other than as Drugs for Plant-Derived Chemicals	5
C. Apathy in Plant-Derived Drug Development	6
D. Current Level of Worldwide Research on Plant- Derived Drugs	10
E. Pharmacological Screening Programs for Plant Extracts	14
I. Random Selection Approach	14
II. Selection of Plants Containing Specific Types of Chemical Compounds	15
III. Selection of Plants Based on a Combination of Criteria	16
F. Problems in the Pharmacological Screening of Extracts from Higher Plants	17
I. Variation from Sample to Sample	17
II. Unexpected Dose-Response Relationships	17
III. Variation Within Samples from the Same Lot of Plant Material	18
IV. Failure to Obtain Positive Results with an Extract Containing Active Principles	19
V. Miscellaneous Considerations in Screening Plant Extracts	20
G. Prospects for the Future	21
References	22
 Pharmacological Approaches to Natural Product Screening and Evaluation	
M.H. MALONE (With 6 Figures)	23
A. Ideal Requirements for a Primary Screen	23
B. Past Approaches to Primary Pharmacological Screening	24
I. Single Technique-Single Goal Screening	25
II. Screening Using a Battery of Specific Procedures	25
III. Single Technique-Multiple Goals Screening	25
IV. Combinations of Specific and Multipurpose Procedures	26
C. Multidimensional Primary Screening	27
I. The Rat "Hippocratic" Screen	27

1. Variations of Hippocratic Screening	30
2. Computerized Hippocratic Evaluation	31
II. The Mouse Multidimensional Screen	35
III. Relative Merits of the Mouse and Rat Primary Screens	35
D. Multidimensional Secondary Screening of Extracts and Pure Compounds	37
I. The Dog Pharmacodynamic Screen	38
II. Other Approaches to Secondary Evaluation ..	39
E. Tertiary Evaluation	40
F. Addendum-Sample Print-Out of Computerized Hippocratic Evaluation	41
References	50

Recent Experimental and Clinical Data Concerning Antitumor and Cytotoxic Agents from Plants

G.A. CORDELL	54
A. Introduction	54
B. Terpenoids	55
I. Sesquiterpenes	55
II. Diterpenes	57
III. Simaroubolides	59
C. Miscellaneous Compounds	60
D. Alkaloids	61
I. Pyrrolizidine Alkaloids	62
II. Isoquinoline Alkaloids	62
III. Benzophenanthridines	63
IV. Miscellaneous Alkaloids	65
V. Monomeric Indole Alkaloids	66
VI. Camptothecine	67
VII. <i>Cephalotaxus</i> Alkaloids	68
VIII. Dimeric Indole Alkaloids	70
IX. Maytansinoids	74
E. Summary	75
References	75

Recent Advances in the Field of Antibiotics

CH. TAMM (With 25 Figures)	82
A. Introduction	82
B. Acetate/Propionate-Derived Metabolites	83
I. Tetracyclines	83
II. Anthracyclines	85
III. Aflatoxins	86
IV. Macrolides	87
V. Cytochalasans	88
VI. Polyethers	91
VII. Macrotetrolides	92
VIII. Nonadrides	93
IX. Ansamycins	94
X. Ovalicin and Pseurotins	95
C. Isoprenoid Metabolites	96
D. Amino Acid-Derived Metabolites	100
I. Penicillins and Cephalosporins	100
II. Other Natural β -Lactams	102
III. Cyclic Polypeptides	102
E. Conclusion	104
References	104

Progress in the Chemistry of Alkaloids with Pharmacological or Biological Activity	
H. ACHENBACH (With 7 Figures)	108
References	132

Plant Mono-, Di- and Sesquiterpenoids with Pharmacological or Therapeutical Activity	
O. STICHER (With 23 Figures)	137
A. Introduction	137
B. Classification	137
C. General Biological Properties	137
D. Monoterpenes	140
I. Normal Monoterpenes	140
1. Antiseptic, Disinfectant, Anthelmintic Properties	142
2. Irritant, Skin Stimulant, Expectorant, Diuretic Properties	143
3. Sedative, Carminative, Spasmolytic Properties	144
II. Cyclopentanoid Monoterpenes and Derivatives	145
1. Biological Activity of the Methylcyclopentanoid Monoterpenes of the Nepetalactone Type	148
2. Pharmacological Activity of the Iridoids and Secoiridoids	148
Antimicrobial Activity	148
Hypotensive Effect	150
Analgetic and Antiphlogistic Properties	150
Bitter Tonic	152
Sedative Agents	153
Laxative Properties	153
Antileukemic Activity	155
Various Other Effects	155
3. Cantharidin	156
E. Sesquiterpenes and Diterpenes	157
I. Antiphlogistic and Spasmolytic Agents	157
II. Bitter Substances	159
III. Antitumor Activity	160
F. Conclusion	165
References	166

Saponins with Biological and Pharmacological Activity

S. SHIBATA (With 9 Figures)	177
A. Introduction	177
B. Saponins of Licorice	178
I. Corticoidal Activities of Glycyrrhizin	178
II. Antiinflammatory Activities of Glycyrrhizin	179
III. Antigastric Ulcer Effects of Glycyrrhizin	180
IV. Metabolic Effects of Glycyrrhizin	180
C. The Saponins of Bupleuri Radix and Platycodi Radix	180
D. Saponins of <i>Polygalae</i> Radix and <i>Senegae</i> Radix	183
E. Saponins of <i>Akebiae</i> <i>Vitis</i>	184

F. Aescin, the Saponins of the Seeds of <i>Aesculus hippocastanum</i>	184
G. Saponins of Ginseng	185
I. Chemical Studies on the Saponins and Saponins of Ginseng and its Congeners	185
II. Pharmacological and Biochemical Studies on Ginseng Saponins	187
III. Pharmacological Studies on Japanese Chikusetsu-Ginseng	190
H. Saponins of <i>Zizyphus Spinosi</i> Semen	191
I. Concluding Remarks	192
References	192

Dimeric Natural Compounds with Pharmacological Activity

A.E. SCHWARTING	197
A. Definitions and Classification	197
B. The Formation of Dimeric Compounds	203
C. Pharmacological and Physiological Activity	205
I. Lignans	206
II. Dimeric Photosensitizers	209
III. Coumarins	209
References	210

Chemical and Biological Investigations on Indian Medicinal Plants

T.R. GOVINDACHARI (With 21 Figures)	212
A. Introduction	212
B. Alkaloids	212
I. Tylophora Alkaloids	212
II. Ancistrocladus Alkaloids	213
III. Alkaloids of <i>Croton sparsiflorus</i> Morong	214
IV. Alkaloids of <i>Mappia foetida</i> Miers	214
V. Alkaloids of <i>Piper trichostachyon</i> C.Dc.	214
VI. Alkaloids from some Menispermaceae Plants ..	215
1. Alkaloids from <i>Tiliacora racemosa</i> Colebr....	215
2. Alkaloids of <i>Cocculus pendulus</i> (Forsk) Diels and <i>Cocculus laurifolius</i> Dc.	216
3. Alkaloids of <i>Cissampelos pareira</i> Linn.	216
C. Oxygen Heterocycles	216
I. Cryptocaryalactone and Cryptocaryone	216
II. Surangin A and B	217
III. Tuberosin	217
D. Terpenoids	217
I. Sesquiterpenes of <i>Cedrus deodara</i> Loudon	217
II. Enhydrin	218
III. Tagitinins A and F	218
IV. Coleonol	218
V. Diosbulbine	218
VI. Dysobinin	218
VII. Triterpenes of <i>Salacia prinoidea</i> DC	219
E. Glycosides	219
I. Cleistanthin	219
II. Ipolearoside	220
III. Stigmasta-7, 22-diene-3 β -O-glucoside	220
IV. Scutellarein-5-glucuronide	220

V. Glycosides of <i>Picrorhiza kurroa</i> Benth.	220
VI. Asclepin	220
VII. Shatavarins I - IV	221
VIII. Glycosides of <i>Carissa</i> Species	221
IX. Peruvoside	221
F. Miscellaneous	222
I. Curcumine	222
II. Arnebin	222
III. Diospyrol	222
IV. Steroidal Constituents of <i>Commiphora mukul</i> ...	222
References	224

Chemistry of Neolignans with Potential Biological Activity

O.R. GOTTLIEB (With 20 Figures)	227
A. Introduction	227
B. Benzofuranoid Neolignans	229
I. Di- and Tetrahydrobenzofurans	229
II. Hexahydrobenzofurans	233
C. Benzodioxane and Other Neolignans	236
D. Bicyclo [3,2,1] octanoid Neolignans	239
E. Biogenesis of Neolignans	242
F. Conclusion	244
References	246

Natural Substances with Effects on the Liver

G. VOGEL (With 20 Figures)	249
References	262

The Modification of Natural Substances in the Modern Drug Synthesis

P.W. THIES (With 21 Figures)	266
A. Introduction	266
B. Main Part	267
I. Steroids and Prostanoids	267
II. "Chemotherapy"	268
III. <i>Claviceps Purpurea</i>	270
1. Peptide Alkaloids (13-15)	272
(a) Ergotamine(2)	272
(b) Dihydroergotamine	272
(c) Dihydroergotoxines	272
(d) 2-Bromo- α -ergocryptine = CB 154 (16). ..	273
2. Low-Molecular Lysergic Acid Derivatives ..	273
Lysergic Acid Diethylamide	273
Methylergobasine	273
Methysergide	273
IV. Opiates	274
V. Cannabinoids	276
VI. Natural Substances in the Role of Raw Material for Drug Synthesis and Biochemical Model Reactions	277
References	282

Subject Index	284
---------------------	-----